Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
Paper is First in a Series Based on Presentations from Cervical
Cancer Prevention Forum Hosted by SGO
CHICAGO, Aug. 3 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) has published the first in a series of four papers on a variety of cervical
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical
cancer vaccine is published today in The Lancet . The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix (R) is highly effective at protecting against the two most common cervical
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
ORLANDO, Fla., May 31 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at thr...
Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE) , a San Diego based medical device company, announced today that Iowa's Des Moines Register published an article reporting that its LUMA cervical
imaging system is enhancing the effectiveness of cancer ...
Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
QIAGEN donates one million tests to expand access to HPV screening in the world's poorest countries
VENLO, Netherlands, April 1 /PRNewswire-FirstCall/ -- Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonst...
First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
QIAGEN's careHPV test provides 'substantially more accurate' front-line screening
VENLO, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- A new HPV test
developed by QIAGEN specifically for use in regions of the world with
scarce resources is "substantially" more a...
Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
HANOI, Vietnam, June 6 /PRNewswire-FirstCall/ -- QIAGEN was featured
this week for its efforts to eliminate cervical
cancer at the 14th annual
Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to this
prominent international platform to issue a call to other leaders in
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
HILDEN, Germany, May 21 /PRNewswire-FirstCall/ --
- Research Supports Replacement of Pap With HPV Test as Front-line
Long-term data from a study published in the International Journal of
Cancer show that women screened only with a human papillomavirus (HPV) DNA
test are half as like...
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses Further Supporting the Therapeutic Potential of HspE7
SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals
Corporation (TSX: NVN) today announced positive immunological data from the
third cohort of...
Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
MIAMI, May 8 /PRNewswire/ -- Globus Medical, Inc., the largest
privately held spinal implant manufacturer in the world and a recognized
leader in motion preservation technology, today announced the completion of
enrollment in its SECURE(R)-C Cervical
Artificial Disc IDE study. The
Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
- HspE7 Phase 2 Trial for Cervical
Dysplasia to Begin Mid-2008 -
SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals
Corporation (TSX: NVN) today announced the completion of the safety and
tolerability assessment of the fourth and final cohort of patients in its
Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated
(Nasdaq: GPRO ) announced today that the Company has begun a pivotal U.S.
clinical trial of its investigational APTIMA(R) assay to detect human
papillomavirus (HPV), which causes cervical
"Starting this highly comp...
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
3 out of 4 Patients in Cohort 2 Demonstrate T-Cell Responses Indicating Potential HspE7 Therapeutic Benefit
SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals
Corporation (TSX: NVN) today announced interim immunological data from the
first two cohorts of i...
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals
Corporation (TSX: NVN) today announced that the Company has completed
enrollment and initiated dosing of the fourth and final cohort of patients
in its Phase 1 dose escalation trial. This study examines the safety of its
GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
New study results also demonstrate the longest duration of consistently high antibody levels shown by a cervical
TAMPA, Fla., March 10 /PRNewswire-FirstCall/ -- New data demonstrate
that GlaxoSmithKline's (NYSE: GSK ) cervical
cancer candidate vaccine,
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly -
SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals
Corporation (TSX: NVN) today announced the completion of the safety and
tolerability assessment of its third cohort of patients in a Phase 1
clinical trial o...
New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
NORTH BRUNSWICK, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Researchers
testing a vaccine based on the live bacteria Listeria, in women with
cancer found it to be safe. The Lovaxin C vaccine being
developed by Advaxis Inc. (OTC Bulletin Board: ADXS), is intended to treat
The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
Cancer Coalition unites women in joining the fight for
education and early detection and prevention of the Human Papillomavirus (HPV) and cervical
WASHINGTON, Sept. 21 /PRNewswire-USNewswire/ -- More than 80 women and
men gathered at the Hyatt R...
Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
KATRINA EVACUEE BENEFITS FROM FIRST EVER TWO-LEVEL TOTAL DISC REPLACEMENT PERFORMED IN LOUISIANA
SHREVEPORT, La., Sept. 12 /PRNewswire/ -- The Spine Institute of
Louisiana, in conjunction with SpineMark Corporation, is now offering
cervical spine motion preservation proc...
Nventa Announces Presentation of Positive HspE7 Data from
NCI-Sponsored Clinical Trial in Cervical Dysplasia
- 78 Percent of Patients Showed Complete Response or Reduction of
Lesion Size by More than Fifty Percent -
SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - Nventa
Biopharmaceuticals Corporation today announced the presentation of
positive results from a clinical trial examining the safety an...
Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100
Percent Protection Against Precancerous Lesions Caused By
Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than
New study results also show evidence of additional protection
against infection with other cancer-causing virus types
LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- The
cancer candidate vaccine, CERVARIX(R),
demonstrated 100 percent efficacy in preventing precancero...
New England Journal of Medicine Publishes New Data on Gardasil,
Merck's Cervical Cancer Vaccine
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-May 10, 2007--Today, the
New England Journal of Medicine is publishing results from two
Phase III studies of Merck's cervical
cancer vaccine, Gardasil
(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
Recombinant Vaccine). In the first study, Gardasi...
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
New Study Results Show Antibodies Against Cancer-Causing Virus
Types 16 & 18 That Are At Least Ten Times Greater Than Natural
CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data show
that at 18 months after the first of a three-dose regimen, 100
percent of women up to ag...
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types
Results also show significant additional protection against
infection with virus types beyond 16 and 18 with the GSK cervical
cancer candidate vaccine
PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Results
from an interim analysis of a Phase III study show that
CERVARIX(R), the GlaxoSmithKl...
Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
LONDON, June 28, 2007--A cervical
cancer vaccine has shown 90%
efficacy for prevention of cervical
cancer and precancerous lesions
associated with the human papillomavirus (HPV) types targeted by
the vaccine, conclude authors of an Article published early Online
and in the upcoming issue of The Lan...
Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
...nd manufactures controlled-release drug delivery products and has a strong focus in the area of women's health, including manufacturing the successful cervical
ripening product, the Cervidil(R) vaginal insert (Propess(R) in Europe and elsewhere). Cytokine PharmaSciences has three products in clinical developm...
University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
...roximately 9,000 American women are diagnosed with cervical
cancer each year despite regular cervical
screening. The study, titled, Development and Eva... be an important advance in the early detection of cervical
Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product
... sepsis and meningitis in newborns, and Human Papilloma Virus (HPV), the most common sexually transmitted infection of which certain types can lead to cervical
Great Basin Scientific's technology has several advantages over the traditional Polymerase Chain Reaction (PCR) method that requires th...
Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
... in upper limb post-stroke spasticity, pre-treated cervical
dystonia, and treatment-naive cervical
dystonia patients represent the second data set pr...pe A free from complexing proteins) in pre-treated cervical
dystonia patients, Efficacy and safety of NT-201 (...
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
...clinical trials in patients with blepharospasm and cervical
dystonia -- one placebo-controlled spasticity tria...ations of symptomatic management of blepharospasm, cervical
dystonia and post-stroke spasticity of the upper l...1 to one other botulinum toxin in the treatment of cervical
dystonia," said Pappert.
First Study - Ti...
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
...o controlled multi-center studies in patients with cervical
dystonia and blepharospasm, and pooled European ef...ations of symptomatic management of blepharospasm, cervical
dystonia and post-stroke spasticity of the upper l...linum neurotoxin free from complexing proteins) in cervical
dystonia, poster p07.081 , Clinical efficacy in...
BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
...he lung likely impairs respiratory function and contributes to sinopulmonary infections. Odontoid dysplasia and ligamentous laxity can commonly cause cervical
spinal instability and potentially spinal cord compression. Other symptoms may include recurrent infections, hearing loss, corneal clouding, and heart...
Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery
...nt of gynecologic malignancies such as uterine and cervical
cancer," explains Dr. M. Patrick Lowe, Director of... the patient. Patients who suffer from uterine and cervical
cancer are the most viable candidates for robotic-...aditional surgery for the treatment of uterine and cervical
About the Society of Gynecologic ...
Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
...r (low back) region are low risk, injections in
the thoracic (mid back) and cervical
(neck) region have the risk of injury to
the spinal cord and brain. It usu...are giving very high volumes (up to 10 cc) of steroids in areas
such as the cervical
epidural space. In limited enclosed areas like the
cervical region that vo...
Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
...reased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical
cancers (see WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest ...
Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
...e test is as
a general screen, in combination with cervical
cytology (pap test), to help
guide patient managem...9.1%. Patients with CIN2 are at
risk of developing cervical
cancer, however this risk is not as high as it
is ...which are
responsible for approximately 70% of all cervical
cancers. The Cervista(R)
16/18 test is also pendin...
Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
... risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical
cancers (see WARNINGS: Table 1).
-- To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the ...
Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds
fragility fracture in their lifetime. The mortality rate due to
osteoporosis-related fractures is greater than the rates for breast cancer
cancer combined," said study lead author Richard M. Dell, MD,
an orthopedic surgeon at the Kaiser Permanente Bellflower Medical Center.
"Yet it's a mi...
CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
...ines, Australia and New Zealand. The licensing agreement
initially focuses on the areas of head and neck cancer, nasopharyngeal
cancer and potentially cervical
As part of this new agreement, Orient Europharma will invest $500,000
in CEL-SCI and fund a portion of the Company's global Phase III clinic...
Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants
...s research grants, this
represents an amazing step in our promise to end breast cancer forever."
Dr. Burack's project will provide Breast Cancer and cervical
Program (BCCCP) services to underinsured and at-risk women in Wayne County.
Dr. Hammad's ACCESS project will continue to provide an extensive ...